Stopping Oral Steroid-Sparing Agents at Initiation of Rituximab in Myasthenia Gravis


Myasthenia Gravis is an autoimmune disorder in which antibodies develop against components of the post-synaptic neuromuscular junction membrane [1]. Patients present with skeletal muscle weakness involving extraocular, bulbar and appendicular muscles and, less commonly, the diaphragm. The two most common antigens are the acetylcholine receptor [2] in 85% of patients and muscle specific kinase [3–6] in 10% of patients. Other newly discovered rarer antigens include low-density lipoprotein receptor-related protein 4 (Lrp4) [7–9] and agrin [10–12].


Leave A Reply